I'd like to reiterate that in those international relationships and through collaboration, a national pharmacare can not only contribute data, but that frequently with orphan drugs the companies control almost all of the evidence that's available. By having a national pharmacare that negotiates, you can negotiate not only price, but also the site of the data they hold and accumulate through their registries, to help Canada more rapidly get an understanding of the true value.
I think there are a lot of opportunities in what Dr. Wong-Rieger was describing, not just at the regulatory level but at the national pharmacare reimbursement and related research level as well.